- Home
- NVT vs BMRN Comparison
NVT vs BMRN Comparison
Compare NVT & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVT
- BMRN
- Stock Information
- Founded
- NVT 1903
- BMRN 1996
- Country
- NVT United Kingdom
- BMRN United States
- Employees
- NVT N/A
- BMRN N/A
- Industry
- NVT Industrial Machinery/Components
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- NVT Industrials
- BMRN Health Care
- Exchange
- NVT Nasdaq
- BMRN Nasdaq
- Market Cap
- NVT 10.7B
- BMRN 12.1B
- IPO Year
- NVT N/A
- BMRN 1999
- Fundamental
- Price
- NVT $65.79
- BMRN $58.07
- Analyst Decision
- NVT Strong Buy
- BMRN Buy
- Analyst Count
- NVT 9
- BMRN 22
- Target Price
- NVT $69.89
- BMRN $93.43
- AVG Volume (30 Days)
- NVT 2.1M
- BMRN 2.2M
- Earning Date
- NVT 05-02-2025
- BMRN 05-01-2025
- Dividend Yield
- NVT 1.22%
- BMRN N/A
- EPS Growth
- NVT 1.65
- BMRN 152.82
- EPS
- NVT 3.49
- BMRN 2.71
- Revenue
- NVT $3,083,300,000.00
- BMRN $2,950,227,000.00
- Revenue This Year
- NVT $18.99
- BMRN $12.27
- Revenue Next Year
- NVT $8.97
- BMRN $10.08
- P/E Ratio
- NVT $45.73
- BMRN $21.47
- Revenue Growth
- NVT 15.90
- BMRN 19.36
- 52 Week Low
- NVT $41.71
- BMRN $52.93
- 52 Week High
- NVT $83.75
- BMRN $94.85
- Technical
- Relative Strength Index (RSI)
- NVT 60.95
- BMRN 41.32
- Support Level
- NVT $63.15
- BMRN $57.27
- Resistance Level
- NVT $67.60
- BMRN $59.12
- Average True Range (ATR)
- NVT 1.75
- BMRN 1.40
- MACD
- NVT -0.29
- BMRN 0.06
- Stochastic Oscillator
- NVT 43.49
- BMRN 18.34
About NVT nVent Electric plc
nVent is a leading global provider of electrical connection and protection solutions that touches a broad range of end markets including infrastructure, industrial, commercial, and residential. NVent designs, manufacturers, markets, installs, and services a portfolio of electrical enclosures and electrical fastening solutions. North America accounts for the majority of sales.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.